Advertisement

Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

Pharming (Group)

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. Ruconest® (Rhucin® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (STO: SOBI). Rhucin® is partnered in North America with Santarus Inc (NASDAQ: SNTS) where the drug is undergoing Phase III clinical development. The product is also under development for follow-on indications, i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products. *

 

Period Start 1989-01-01 established
Product Industry transgenic animal
Person Person de Vries, Sijmen (Pharming 200810– CEO before 4-Antibody CEO before Morphochem before Novartis + SKB)
     
Region Region Leiden
  Country Netherlands
  Street 24 Darwinweg
  City 2333 CR Leiden
  Tel +31-71-5247-400
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency EUR
  Cash 13,500,000 (2013-09-30)
     
    * Document for �About Section�: 
     
   
Record changed: 2018-10-30

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Pharming (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px




» top